Emerging drugs of abuse

Disease-a-Month

Volumn 60, Issue 3, 2014, Pages 110-132

  Nelson, Michael E ^a   Bryant, Sean M ^a   Aks, Steven E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; ANABOLIC AGENT; ANTIDOTE; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CANNABINOID; CANNABINOID DERIVATIVE; CANNABIS; CATHINONE; COCAINE; CODEINE; CONTROLLED SUBSTANCE; DEXANABINOL; DIAMORPHINE; KETAMINE; LAXATIVE; MORPHINE; NICOTINIC ACID; NON PRESCRIPTION DRUG; PERFORMANCE ENHANCING SUBSTANCE; PHENETHYLAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; PRESCRIPTION DRUG; TAURINE; TRYPTAMINE DERIVATIVE;

ARGYREIA NERVOSA; ARTIFICIAL VENTILATION; ATTENTION DEFICIT DISORDER; CAUSE OF DEATH; CONVOLVULACEAE; DETOXIFICATION; DRUG ABUSE; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG OVERDOSE; DRUG WITHDRAWAL; ENERGY DRINK; EPIDEMIC; GANGRENE; HISTORY OF MEDICINE; HUMAN; INTERNET; INTUBATION; KIDNEY DYSFUNCTION; LAW; LAW ENFORCEMENT; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MITRAGYNA; MITRAGYNA SPECIOSA; MUSHROOM; NECROSIS; PATIENT EDUCATION; PHARMACIST; PHYSICIAN; POISON CENTER; PRESCRIPTION; RESPIRATION CONTROL; REVIEW; RHABDOMYOLYSIS; SALVIA; SEARCH ENGINE; SKIN DEFECT; SOCIAL MEDIA; SOFT TISSUE INFECTION; SUBSTANCE ABUSE; TANDEM MASS SPECTROMETRY;

HUMANS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84895797441     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2014.01.001     Document Type: Review

References (188)

1. Chary M., Genes N., McKenzie, et al. Leveraging social networks for toxicovigilance. J Med Toxicol 2013, 10.1007/s13181-013-0299-6.
2. Deluca P., Davey Z., Corazza O., et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:221-226.
3. Gibbons S. "Legal highs"-novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin Toxicol 2012, 50:15-24.
4. Sutter M.E., Chenoweth J., Albertson T.E. Alternative drugs of abuse. Clin Rev Allerg Immunol 2013, 10.1007/s12016-013-8370-2.
5. Aleksander I. Molly: Pure But Not So Simple. 〈 2013 Accessed 24.6.13. http://www.nytimes.com/2013/06/23/fashion/molly-pure-but-not-so-simple.html?pagewanted=1&_r=1&hpw&.
6. Okie S. The flood of opioids: a rising tide of deaths. N Engl J Med 2010, 363(21):1981-1985.
7. Ibanez G.E., Levi-Minzi M.A., Rigg K.K., et al. Diversion of benzodiazepines through healthcare sources. J Psychoactive Drug 2013, 45:48-56.
8. Nelson A., Galon P. Exploring the relationship among ADHD, stimulants, and substance abuse. J Child Adolesc Psychiatr Nurs 2012, 25:113-118.
9. Paulozzi L.J., Kilbourn E.M., Desai H.A. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011, 12:747-754.
10. Manchikanti L. National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician 2007, 10:399-424.
11. Pomeranz J.L., Taylor L.M., Austin S.B. Over-the-counter and out-of-control: legal strategies to protect youths from abusing products for weight control. Am J Pub Health 2013, 103:220-225.
12. Grund J.P.C., Latypov A., Harris M. Breaking worse: the emergence of krokodil and excessive injuries among people who inject drugs in Eurasia. Int J Drug Policy 2013, 24:265-274.
13. Booth R. Krokodil and other home-produced drugs for injection: a perspective from Ukraine. Int J Drug Policy 2013, 24:277-278.
14. Brennan B.P., Kanayama G., Pope H.G. Performance-enhancing drugs on the web: a growing public-health issue. Am J Addict 2013, 22:158-161.
15. Thevis M., Kuuranne T., Geyer H., et al. Annual banned-substance review: analytical approaches in human sports drug testing. Drug Test Anal 2013, 5:1-19.
16. Nelson M.E., Bryant S.M., Aks S.E. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol 2012, 50(10):1165-1168.
17. Ward J., Rhyee S., Plansky J., et al. Methoxetamine: a novel ketamine analog and growing health-care concern. Clin Toxicol 2011, 49:874-875.
18. Wolk B.J., Ganetsky M., Babu K.M. Toxicity of energy drinks. Curr Opin Pediatr 2012, 24(2):243-251.
19. Adams I.B., Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996, 91:1586-1614.
20. Gunderson E.W., Haughey H.M., Ait-Daoud N., et al. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 2012, 21:320-326.
21. Seely K.A., Lapoint J., Moran J.H., Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:234-243.
22. Seely K.A., Prather P.L., James L.P., Moran J.H. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse. Mol Interv 2011, 11(1):36-51.
23. Auwärter V., Dresen S., Weinmann W., et al. Spice and other herbal blends: harmless incense or cannabinoid designer drugs?. J Mass Spectrom 2009, 44:832-837.
24. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Understanding the 'Spice' phenomenon. European Monitoring Centre for Drugs and Drug Addiction EMCDDA 2009 Thematic paper ed: Office for Official Publications of the European Committees; 2009:1-34.
25. Vardakou I., Pistos C., Spiliopoulou C.H. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010, 197:157-162.
26. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Synthetic Cannabinoids and 'Spice.' 〈 Accessed 6.6.13. http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids.
27. Einhorn L., Nagy C., Furnas B., Williams S. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 1981, 21(suppl 8-9):64S-69S.
28. United States Adopted Names Council. Statement on a Nonprioprietary Name. 〈 Accessed 4.6.13. http://www.ama-assn.org/ama1/pub/upload/mm/365/nabiximols.pdf.
29. Weissman A., Milne G.M., Melvin L.S. Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J Pharmacol Exp Ther 1982, 223(2):516-523.
30. Bell M.R., D'Ambra T.E., Kumar V., et al. Antinociceptive (aminoalkyl)indoles. J Med Chem 1991, 34(3):1099-1110.
31. Rosenbaum C.D., Carreiro S.P., Babu K.M. Here today, gone tomorrow and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012, 8(1):15-32.
32. Huffman J.W., Dai D. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett 1994, 4(4):563-566.
33. Huffman J.W., Yu S., Showalter V., et al. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 1996, 39(20):3875-3877.
34. Wiley J.L., Comptom D.R., Dai D., et al. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 1998, 285(3):995-1004.
35. Huffman J.W. Cannabimimetic indoles, pyrroles, and indenes: structure-activity relationships and receptor interactions. The Cannabinoid Receptors, 1 2009, 49-94. Humana Press, New York. P.H. Reggio (Ed.).
36. 1 receptor agonist. Br J Pharmacol 2010, 160:585-593.
37. Lapoint J., James L.P., Moran C.L., et al. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol 2011, 49:760-764.
38. Wood K.E. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J Pediatr 2013, 163(1):213-216.
39. Drug Enforcement Administration (DEA). Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids into Schedule I [FR Doc No: 11075-11078]. 〈 Accessed 5.6.13. http://www.deadiversion.usdoj.gov/fed_regs/rules/2011/fr0301.htm.
40. Moran C.L., Le V.H., Chimalakonda K.C., et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 2011, 83(11):4228-4236.
41. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on drug use: 2012 Overview, Key Findings on Adolescent Drug Use. 2013. Ann Arbor: Institute for Social Research, The University of Michigan. 〈 Accessed 6.6.13. http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2012.pdf.
42. Heltsley R., Shelby M.K., Crouch D.J., et al. Prevalence of synthetic cannabinoids in U.S. athletes: initial findings. J Anal Toxicol 2012, 36:588-593.
43. Hoyte C.O., Jacob J., Monte A.A., et al. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 2012, 60(4):435-438.
44. Forrester M.B., Kleinschmidt K., Schwarz E., Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol 2012, 31(10):1006-1011.
45. Winstock A.R., Barratt M.J. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013, 131(1-2):106-111.
46. Lank PM, Pines E, Mycyk MB. Emergency physicians[U+05F3] knowledge of cannabinoid designer drugs. West J Emerg Med 2013;14(5):467-470.
47. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999, 58:315-348.
48. Pertwee R.G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 2010, 17(14):1360-1381.
49. Gronewold A., Skopp G. A preliminary investigation on the distribution of cannabinoids in man. Forensic Sci Int 2011, 210:e7-e11.
50. Shim J.Y., Welsh W.J., Howlett A.C. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers 2003, 71:169-189.
51. Teske J., Weller J.P., Fieguth A., et al. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2659-2663.
52. Brents L.K., Reichard E.E., Zimmerman S.M., et al. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 2011, 6:e21917.
53. Rajasekaran M., Brents L.K., Franks L.N., et al. Human metabolites of synthetic cannabinioids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol 2013, 269:100-108.
54. Castellanos D., Singh S., Thornton G., et al. Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 2011, 49:347-349.
55. Hurst D., Loeffler G., McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 2011, 168(10):1119.
56. Müller H., Sperling W., Köhrmann M., et al. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010, 118:309-310.
57. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 2011, 117:152-157.
58. Schneir A.B., Cullen J., Ly B.T. "Spice" girls: synthetic cannabinoid intoxication. J Emerg Med 2011, 40(3):296-299.
59. Schneir A.B., Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 2012, 8:62-64.
60. Tofighi B., Lee J.D. Internet highs-seizures after consumption of synthetic cannabinoids purchased online. J Addict Med 2012, 6(3):240-241.
61. Pant S., Deshmukh A., Dholaria B., et al. Spicy seizure. Am J Med Sci 2012, 344(1):67-68.
62. Mir A., Obafemi A., Young A., Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011, 128(6):e1622-e1627.
63. Simmons J.R., Skinner C.G., Williams J., et al. Intoxication from Smoking "Spice". Ann Emerg Med 2011, 57(2):187-188.
64. Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morb Mortal Wkly Report 2012, 62(6):93-98. Centers for Disease Control and Prevention.
65. Alhadi S., Tiwari A., Vohra R., et al. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol 2013, 9:199-206.
66. Fattore L., Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011, 5:1-12.
67. Bronstein A.C., Spyker D.A., Cantilena L.R., et al. 2011 Annual Report of the American Association of Poison Control Centers[U+05F3] National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol 2012, 50:911-1164.
68. Meier M.H., Caspi A., Ambler A., et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 2012, 109(40):E2657-E2664.
69. Duffy A., Milin R. Case study: withdrawal syndrome in adolescent chronic cannabis users. J Am Acad Child Adolesc Psychiatry 1996, 35(12):1618-1621.
70. Haney M. The marijuana withdrawal syndrome: diagnosis and treatment. Curr Psychiatry Rep 2005, 7:360-366.
71. Nacca N., Vatti D., Sullivan R., et al. The synthetic cannabinoid withdrawal syndrome. J Addict Med 2013, 7(4):296-298.
72. Zimmermann U.S., Winkelmann P.R., Philhatsch M., et al. Withdrawal phenomena and dependence syndrome after the consumption of "Spice Gold". Dtsch Arztebl Int 2009, 106:464-467.
73. National Medical Services (NMS) labs. NMS Labs Online Test Catalog. 〈 2013 Accessed 10.6.13. http://www.nmslabs.com/test-catalog/synthetic%20cannabinoids@0.
74. World Health Organization Expert Committee on Drug Dependence. Assessment of Khat (Catha edulis Forsk). 2006. 34th ECDD. 〈 Accessed 11.6.13. http://www.who.int/medicines/areas/quality_safety/4.4KhatCritReview.pdf.
75. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012, 8(1):33-42.
76. Brenneisen R., Fisch H.U., Koelbing U., et al. Amphetamine-like effects in humans of the khat alkaloid cathinone. Br J Clin Pharmacol 1990, 30(6):825-828.
77. Ali W.M., Zubaid M., Al-Motarreb A., et al. Association of Khat chewing with increased risk of stroke and death in patients presents with acute coronary syndrome. Mayo Clin Proc 2010, 85(11):974-980.
78. Hyde J.F., Browning E., Adams R. Synthetic homologs of d,l-ephedrine. J Am Chem Soc 1928, 50(8):2287-2292.
79. Emerson T.S., Cisek J.E. Methcathinone: a Russian designer amphetamine infiltrates the rural Midwest. Ann Emerg Med 1993, 22(12):1897-1903.
80. Mehta MB. United States Patent 3,819,706: Meta-Chloro Substituted α-Butylamino-Propiophenones. United States Patent and Trademark Office (USPTO). 〈 1974 Accessed 13.6.13. http://patimg1.uspto.gov/.piw?Docid=03819706&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO1%2526Sect2%3DHITOFF%2526d%3DPALL%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsrchnum.htm%2526r%3D1%2526f%3DG%2526l%3D50%2526s1%3D3819706.PN.%2526OS%3DPN%2F3819706%2526RS%3DPN%2F3819706&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page.
81. United States Drug Enforcement Administration. Methcathinone. 〈 2013 Accessed 13.6.13. http://www.justice.gov/dea_old/concern/methcathinone.html.
82. Psychonaut Web Mapping Research Group. Mephedrone. London, UK, Institute of Psychiatry, King's College London. 〈 2009 Accessed 13.6.13. http://www.psychonautproject.eu/newsletters/n2.php.
83. Dargan P.I., Albert S., Wood D.M. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. Q J Med 2010, 103:875-879.
84. Winstock A.R., Mitcheson L.R., Deluca P., et al. Mephedrone, new kid for the chop?. Addiction 2010, 106:154-161.
85. Warrick B.J., Hill M., Hekman K., et al. A 9-state analysis of designer stimulant, "bath salt," hospital visits reported to Poison Control Centers. Ann Emerg Med 2013, 62(3):244-251.
86. American Association of Poison Control Centers. Bath Salts Data. 〈 2013 Accessed 14.6.13. https://aapcc.s3.amazonaws.com/files/library/Bath_Salts_Data_for_Website_5.31.2013.pdf.
87. American Association of Poison Control Centers. Synthetic Marijuana Data. 〈 2013 Accessed 14.6.13. https://aapcc.s3.amazonaws.com/files/library/Synthetic_Marijuana_Data_for_Website_5.31.2013.pdf.
88. Winstock A., Mitcheson L., Marsden J. Mephedrone: still available and twice the price. Lancet 2010, 376:1537.
89. Gibbons S., Zloh M. An analysis of the 'legal high' mephedrone. Bioorg Med Chem Lett 2010, 20:4135-4139.
90. Notice of intent-scheduled of controlled substances: temporary placement of three synthetic cathinones into schedule I. Microgram Bull 2011, 44(9):57-65. US Department of Justice DEA.
91. 112th Congress (webpage on Internet). S. 3190: Synthetic Drug Abuse Prevention Act of 2012. Sec 2. Addition of Synthetic Drugs to Schedule I of the Controlled Substances Act. Washington, DC: Library of Congress. 〈 2012 Accessed 2.7.13. http://www.govtrack.us/congress/bills/112/s3190/text.
92. Hill S.L., Thomas S.H.L. Clinical toxicology of newer recreational drugs. Clin Toxicol 2011, 49:705-719.
93. Marinetti L.J., Antonides H.M. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol 2013, 37:135-146.
94. James D., Adams R.D., Spears R., et al. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 2011, 28(8):686-689.
95. Schifano F., Albanese A., Fergus S., et al. Mephedrone (4-methylmethcathinone 'meow-meow'): chemical, pharmacological and clinical issues. Psychopharmacology 2011, 214:593-602.
96. Wood D.M., Davies S., Greene S.L., et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 2010, 48:924-927.
97. Coppola M., Mondola R. Synthetic cathinones: chemistry, pharmacology, and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food" Toxicol Lett 2012, 211:144-149.
98. Cameron K., Kolanos R., Vekariya R., et al. Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts," produce opposite effects at the human dopamine transporter. Psychopharmacology 2013, 227:493-499.
99. Cozzi N.V., Sievert M.K., Shulgin A.T., et al. Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Eur J Pharmacol 1999, 381:63-69.
100. Nagai F., Nonaka R., Satoh Hasashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007, 559:132-137.
101. Meyer M.R., Wilhelm J., Peters F.T., Maurer H.H. Beta-ketoamphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 2010, 397(3):1225-1233.
102. Zaitsu K., Katagi M., Tatsuno M., et al. Recently abused β-keto derivatives of 3,4-methylenedioxyphenylalkylamines: a review of the metabolisms and toxicological analysis. Forensic Toxicol 2011, 29:73-84.
103. Meyer M.R., Du P., Schuster F., Maurer H.H. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 2010, 45:1426-1442.
104. Wood D.M., Davies S., Puchnarewicz M., et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 2010, 6:327-330.
105. Murphy C.M., Dulaney A.R., Beuhler M.C., Kacinko S. "Bath salts" and "plant food" products: the experience of one regional US Poison Center. J Med Toxicol 2013, 9:42-48.
106. Nicholson P.J., Quinn M.J., Dodd J.D. Headshop heartache: acute mephedone 'meow' myocarditis. Heart 2010, 96(24):2051-2052.
107. Wyman J.F., Lavins E.S., Engelhart D., et al. Postmortem tissue distribution of MDPV following lethal intoxication by "bath salts". J Anal Toxicol 2013, 37(3):182-185.
108. Penders T.M., Gestring R.E., Vilensky D.A. Excited delirium following the use of synthetic cathinones (bath salts). Gen Hosp Psychiatry 2012, 34:647-650.
109. Thornton S.L., Gerona R.R., Tomaszewksi C.A. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 2012, 8:310-313.
110. Stoica M.V., Felthous A.R. Acute psychosis induced by bath salts: a case report with clinical and forensic implications. J Forensic Sci 2013, 58(2):530-533.
111. Murray B.L., Murphy C.M., Beuhler M.C. Death following recreational use of designer drug "bath salts" containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol 2012, 8:69-75.
112. Olives T.D., Orozco B.S., Stellpflug S.J. Bath salts: the ivory wave of trouble. West J Emerg Med 2012, 13(1):58-62.
113. Boulanger-Gobeil C., St-Onge M., Laliberté M., Auger P.L. Seizures and hyponatremia related to ethcathinone and methylone poisoning. J Med Toxicol 2012, 8:59-61.
114. Winstock A., Mitcheson L., Ramsey J., et al. Mephedrone: use, subjective effects and health risk. Addiction 2011, 106:1991-1996.
115. Warrick B.J., Wilson J., Hedge M., et al. Lethal serotonin syndrome after methylone and butylone ingestion. J Med Toxicol 2012, 8:65-68.
116. Levine M., Levitan R., Skolnik A. Compartment syndrome after "bath salts" use: a case series. Ann Emerg Med 2012, 61(4):480-483.
117. Borek H.A., Holstege C.P. Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med 2012, 60(1):103-105.
118. Rosenberg J., Pentel P., Pond S., et al. Hyperthermia associated with drug intoxication. Crit Care Med 1986, 14(11):964-969.
119. Torrance H., Cooper G. The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int 2010, 202:e62-e63.
120. Carbone P.N., Carbone D.L., Carstairs S.D., Luzi S.A. Sudden cardiac death associated with methylone use. Am J Forensic Med Pathol 2013, 34(1):26-28.
121. Maskell P.D., De Paoli G., Seneviratne C., Pounder D.J. Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 2011, 35:188-191.
122. Sparago M., Wlos J., Yaun J., et al. Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse. J Pharmacol Exp Ther 1996, 279(2):1043-1052.
123. 11C]WIN-35,428. J Neurosci 1998, 18(20):8417-8422.
124. Petrie M., Lynch K.L., Ekins S., et al. Cross-reactivity studies and predictive modeling of "bath salts" and other amphetamine-type stimulants with amphetamine screening immunoassays. Clin Toxicol 2013, 51:83-91.
125. Swortwood M.J., Boland D.M., DeCaprio A.P. Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis. Anal Bioanal Chem 2013, 405:1383-1397.
126. National Medical Services (NMS) labs. NMS Labs Online Test Catalog. 〈 2013 Accessed 18.6.13. http://www.nmslabs.com/test-catalog/bath%20salts@0.
127. Dean B.V., Stellpflug S.L., Burnett A.M., Engebretsen K.M. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 2013, 9:172-178.
128. Shulgin A.T., Shulgin A. PiHKAL-A Chemical Love Story 1991, Transform Press, Berkley, CA.
129. Benzenhöfer U., Passie T. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction 2010, 105:1355-1361.
130. Caudevilla-Gálligo F., Riba J., Ventura M., et al. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. J Psychopharmacol 2012, 26(7):1026-1035.
131. de Boer D., Bosman I. A new trend in drugs-of-abuse; the 2C series of phenethylamine designer drugs. Pharm World Sci 2004, 26:110-113.
132. Giroud C., Augsburger M., Rivier L., et al. 2C-B: a new psychoactive phenethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. J Anal Toxicol 1998, 22:345-354.
133. Sanders B., Lankenau S.E., Bloom J.J., Hathazi D. Research chemicals: tryptamine and phenethylamine use among high-risk youth. Subst Use Misuse 2008, 43389-43402.
134. Topeff J.M., Ellsworth H., Willhite L.A., et al. A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Toxicol 2011, 49(6):526.
135. Maurer H.H. Chemistry, pharmacology, and metabolism of emerging drugs of abuse. Ther Drug Monit 2010, 32(5):544-549.
136. Saez P., Borges Y., Gonzalez E., Cassels B.K. Alpha-adrenergic and 5-HT2-serotonergic effects of some beta-phenylethylamines on isolated rat thoracic aorta. Gen Pharmacol 1994, 25(1):211-216.
137. Carmo H., Hengstler J.G., de Boer D., et al. Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology 2005, 206:75-89.
138. Theobald D.S., Maurer H.H. Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl-β-phenethylamine (2C-D) in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 2006, 41:1509-1519.
139. Theobald D.S., Maurer H.H. Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). Biochem Pharmacol 2007, 73:287-297.
140. Ambrose J.B., Bennett H.D., Lee H.S., Josephson S.A. Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion. Neurologist 2010, 16(3):199-202.
141. Bosak A., LoVecchio F., Levine M. Recurrent seizures and serotonin syndrome following "2C-I" ingestion. J Med Toxicol 2013, 9:196-198.
142. Peters F.T., Martinez-Ramirez J.A. Analytical toxicology of emerging drugs of abuse. Ther Drug Monit 2010, 32(5):532-539.
143. Schep L.J., Slaughter R.J., Vale J.A., et al. The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine. Clin Toxicol 2011, 49:131-141.
144. Staack R.F. Piperazine designer drugs of abuse. Lancet 2007, 369:1411-1413.
145. Davies S., Wood D.M., Smith G., et al. Purchasing 'legal highs' on the Internet-is there consistency in what you get?. Q J Med 2010, 103:489-493.
146. Wilkins C., Sweetsur P., Girling M. Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug Alcohol Rev 2008, 27:633-639.
147. Gee P., Gilbert M., Richardson S. Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol 2008, 46:802-807.
148. Baumann M.H., Clark R.D., Budzynski A.G., et al. Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain. Ann N Y Acad Sci 2004, 1025:189-197.
149. Baumann M.H., Clark R.D., Budzynski A.G., et al. N-Substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 2005, 30:550-560.
150. Arbo M.D., Bastos M.L., Carmo H.F. Piperazine compounds as drugs of abuse. Drug Alcohol Depend 2012, 122:174-185.
151. Bye C., Munro-Faure A.D., Peck A.W., Young P.A.A. Comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 1973, 6:163-169.
152. de Boer D., Bosman I.J., Hidvégi E., et al. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int 2001, 121:47-56.
153. Gee P., Jerram T., Bowie D. Multiorgan failure from 1-benyzlpiperazine ingestion-legal high or lethal high?. Clin Toxicol 2010, 48:230-233.
154. Wilkins C., Sweetsur P. Differences in harm from legal BZP/TFMPP party pills between North Island and South Island users in New Zealand: a case of effective industry self-regulation?. Int J Drug Policy 2010, 21:86-90.
155. Wood D.M., Dargan P.I., Button J., et al. Collapse, reported seizure-and an unexpected pill. Lancet 2007, 369:1490.
156. Balmelli C., Kupferschmidt H., Rentsch K., Schneemann M. Fatal brain edema after ingestion of ecstasy and benzylpiperazine. Dtsch Med Wochenschr 2001, 126:809-811.
157. Elliott S., Smith C. Investigation of the first deaths in the United Kingdom involving the detection and quantification of the piperazines BZP and 3-TFMPP. J Anal Toxicol 2008, 32:172-177.
158. Nichols D.E. Hallucinogens. Pharmacol Ther 2004, 101:131-181.
159. Arunotayanun W., Dalley J.W., Huang X.P., et al. An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'novel psychoactive drugs'. Bioorg Med Chem Lett 2013, 23:3411-3415.
160. Lessin A.W., Long R.F., Parkes M.W. Central stimulant actions of α-alkyl substituted tryptamine in mice. Br J Pharmacol 1965, 24:49-67.
161. Corkery J.M., Durkin E., Elliot S., et al. The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a brief review. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:256-262.
162. Jovel A, Felthous A, Bhattacharyya A. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT. J Forensic Sci. 2013 Dec 13. [Epub ahead of print]. http://dx.doi.org/10.1111/1556-4029.12367.
163. Alatrash G., Majhail N.S., Pile J.C. Rhabdomyolysis after ingestion of 'foxy', a hallucinogenic tryptamine derivative. Mayo Clin Proc 2006, 81:550-551.
164. Brush D.E., Bird S.B., Boyer E.W. Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. Clin Toxicol 2004, 42:191-195.
165. Boland D.M., Andollo W., Hime G.W., Hearn W.L. Fatality due to acute alpha-methyltryptamine intoxication. J Anal Toxicol 2005, 29:394-398.
166. Tanaka E., Kamata T., Katagi M., et al. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy. Forensic Sci Int 2006, 163:152-154.
167. Meyer M.R., Peters F.T. Analytical toxicology of emerging drugs of abuse-an update. Ther Drug Monit 2012, 34(6):615-621.
168. Kikura-Hanjari R., Hayashi M., Saisho K., Goda Y. Simultaneous determination of nineteen hallucinogenic tryptamines/β-calbolines and phenethylamines using gas chromatography-mass spectrometry and liquid chromatography-electron ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 825:29-37.
169. Shellard E.J. Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol 1989, 25:123-124.
170. Boyer E.W., Babu K.M., Macalino G.E., et al. Self-treatment of opioid withdrawal with a dietary supplement, kratom. Am J Addict 2007, 16:352-356.
171. Thongpradichote S., Matsumoto K., Tohda M., et al. Identification of opioid receptor subtypes in antinociceptive actions of supraspinally-administered mitragynine in mice. Life Sci 1998, 62:1371-1378.
172. Suwanlert S.A. Study of kratom eaters in Thailand. Bull Narc 1975, 27:21-27.
173. Nelson J.L., Lapoint J., Hodgman M.J., et al. Seizures and coma following kratom (Mitragynina speciosa Korth) exposure. J Med Toxicol 2010, 6:424-426.
174. Kronstrand R., Roman M., Thelander G., et al. Unintentional fatal intoxications with mitragynine and o-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol 2011, 35:242-247.
175. Kelly B.C. Legally tripping: a qualitative profile of Salvia divinorum use among young adults. J Psychoactive Drug 2011, 43:46-54.
176. Baggott M.J., Erowid E., Erowid F., et al. Use patterns and self-reported effects of Salvia divinorum: an Internet-based survey. Drug Alcohol Depend 2010, 111:250-256.
177. Tsujikawa K., Kuwayama K., Miyaguchi H., et al. In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica 2009, 39:391-398.
178. Rais V., Seefeld A., Cantrell L., et al. Salvia divinorum: exposures reported to a statewide poison control system over 10 years. J Emerg Med 2011, 40:643-650.
179. Przekop P., Lee T. Persistent psychosis associated with Salvia divinorum use. Am J Psychiatry 2009, 166:832.
180. Hatfield G.M., Brady L.R. Toxins of higher fungi. Lloydia 1975, 38:36-55.
181. Curry S.C., Rose M.C. Intravenous mushroom poisoning. Ann Emerg Med 1985, 14:900-902.
182. McClintock R.L., Watts D.J., Melanson S. Unrecognized magic mushroom abuse in a 28-year-old man. Am J Emerg Med 2008, 26. (972.e3-4).
183. Hallock R.M., Dean A., Knecht Z.A., et al. A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. Drug Alcohol Depend 2013, 130:245-248.
184. Klinke H.B., Muller I.B., Steffenrud S., et al. Two cases of lysergamide intoxication by ingestion of seeds from Hawaiian baby woodrose. Forensic Sc Int 2010, 197:e1-e5.
185. Schmidt M.M., Sharma A., Schifano F., et al. "Legal highs" on the net-evaluation of UK-websites, products and product information. Forensic Sci Int 2011, 206:92-97.
186. Kremer C., Paulke A., Wunder C., et al. Variable adverse effects in subjects after ingestion of equal doses of Argyreia nervosa seeds. Forensic Sci Int 2012, 214:e6-e8.
187. Juszczak G.R., Swiergiel A.H. Recreational use of d-lysergamide from the seeds of Argyreia nervosa, Ipomoea tricolor, Ipomoea violacea, and Ipomoea purpurea in Poland. J Psychoactive Drugs 2013, 45:79-93.
188. Rusyniak D.E., Sprague J.E. Toxin-induced hyperthermic syndromes. Med Clin North Am 2005, 89:1277-1296.